As of 2024-12-15, the Relative Valuation of TCR2 Therapeutics Inc (TCRR) is (74.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.48 USD, the upside of TCR2 Therapeutics Inc based on Relative Valuation is -5124.3%.
The range of the Relative Valuation is (46.28) - (78.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 24.1x | 17.3x |
| Forward P/E multiples | 11.1x - 18.9x | 18.5x |
| Fair Price | (46.28) - (78.35) | (74.36) |
| Upside | -3226.8% - -5393.7% | -5124.3% |
| Date | P/E |